Emile van Dongen
Chief Executive Officer at Progress Pharma NV
Profile
Emile van Dongen is currently the Chief Executive Officer at Progress Pharma NV and the Executive Vice President-Sales at Organon BioSciences NV.
Previously, he worked as a Director at Movetis NV and as the Executive Vice President-Global Sales at Organon International, Inc. Mr. van Dongen holds an MBA degree from the University of Georgia.
Emile van Dongen active positions
Companies | Position | Start |
---|---|---|
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Sales & Marketing | - |
Progress Pharma NV
Progress Pharma NV BiotechnologyHealth Technology Progress Pharma NV adopts a business model for asset-centric drug development. The company is headquartered in Vosselaar, Belgium. | Chief Executive Officer | - |
Former positions of Emile van Dongen
Companies | Position | End |
---|---|---|
Movetis NV
Movetis NV Pharmaceuticals: GenericHealth Technology Movetis NV operates as a pharmaceutical company, that focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, and paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company was founded in November 2006 and is headquartered in Turnhout, Belgium. | Director/Board Member | - |
Organon International, Inc.
Organon International, Inc. Pharmaceuticals: MajorHealth Technology Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ. | Sales & Marketing | - |
Training of Emile van Dongen
University of Georgia | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Organon International, Inc.
Organon International, Inc. Pharmaceuticals: MajorHealth Technology Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ. | Health Technology |
Movetis NV
Movetis NV Pharmaceuticals: GenericHealth Technology Movetis NV operates as a pharmaceutical company, that focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, and paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company was founded in November 2006 and is headquartered in Turnhout, Belgium. | Health Technology |
Organon BioSciences NV
Organon BioSciences NV Pharmaceuticals: MajorHealth Technology Organon Biosciences NV specializes in biopharmaceutical manufacturing and distribution services. It develops products in the areas of cardiovascular disease, fertility, gynecology, anesthesia, respiratory, consumer health care, and neuroscience, immunology, animal health, and oncology. The company’s products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, cold/flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. It was founded in 1923 and is headquartered in Oss, the Netherlands. | Health Technology |
Progress Pharma NV
Progress Pharma NV BiotechnologyHealth Technology Progress Pharma NV adopts a business model for asset-centric drug development. The company is headquartered in Vosselaar, Belgium. | Health Technology |
- Stock Market
- Insiders
- Emile van Dongen